Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by TheBearInTheWoodson Dec 30, 2021 8:20pm
82 Views
Post# 34272659

RE:RE:RE:RE:Trading December 29

RE:RE:RE:RE:Trading December 29

As the guy who drove the stock from .58 to .04 stated it's everyone else's fault lmao  


C10H12N2 wrote: As CJM stated, it's a lack of knowledge that will continue holding the company back. When you look at comparisons like Bellus Health they have a one trick pony pipeline for Chronic Cough. You can't tell me the Nasdaq is not the reason for it being propelled to a billion dollar market cap going on twice now without professional analysts propelling it to such heights. Algernon is stuck with one guy from Mackie research analyzing the stock and that guy (Andre Uddin) is a conflict of interest because he represents the book runner for the firesale Private Placements. They have skin in the game. It's some crazy @ss conflicts of interest that are allowed on CSE that will not fly on Nasdaq. The entire level of operations would be on a level above dealing at rock bottom with rock bottom news feeds and the like. Algernon needs free ink that's read globally about what's in the pipeline and the prospects of treatments in multiple needed areas of disease concerns. The current share price is pure insanity by any comparable measure. The folks on CSE and OTC are content with flipping little pennies back and forth for their monthly beer allowance. There's no way Nasdaq will not lift the company out of the mud it consistently waddles in from one year to the next. Nothing is ever enough for the bottom feeders until they have left a company in bankruptcy. Then it's off to the next bash and crash narrative at another company to confuse the issues and turn a company upside down and inside out. This sh!t has gone way too far for far too long. Moreau called out the Canadian market in a direct way. He said they are basically stupid people doing stupid things that are costing all of us a better opportunity at moving forward.

 

<< Previous
Bullboard Posts
Next >>